[Current status of the antitubercular chemotherapy].
D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007539:Isonicotinic Acids / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D011379:Prognosis; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D004338:Drug Combinations; D007539:Isonicotinic Acids; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Zum geganwärtigen Stand der antituberkulösen Chemotherapie.